Cano-Nigenda V, Nader-Kawachi JA, Andrade-Magdaleno ML, González-de la Cruz G, Juárez-Hernández E, Chávez-Tapia N

Language: English
References: 37
Page: 4-9
PDF size: 116.49 Kb.

ABSTRACT

Diabetic neuropathy is one of the microvascular complication of diabetes mellitus. It is classified, as focal or diffuse, and according to the nervous fiber type and its localization, it is classified in to peripheral, autonomic, sensitive or motor neuropathy. Diabetic autonomic neuropathy (DAN) is associated with an increased morbidity and mortality particularly in patients with longstanding-poor controlled diabetes. The main predictors of development of cardiovascular autonomic neuropathy (CAN) in patients with type 2 diabetes are age, gender, ethnicity and presence of other microvascular complications. The main clinical manifestations presented in CAN patients are resting tachycardia, exercise intolerance, orthostatic hypotension, silent ischemia and diabetic cardiomyopathy. Unfortunately, there is no specific treatment of DAN. The mainstay of treatment for this disease is prevention and early detection. This review focuses on epidemiology, physiopathology, clinical manifestations, diagnostic studies and treatment of CAN.

REFERENCES

1. Verrotti A, Prezioso G, Scattoni R, Chiarelli F. Autonomic neuropathy in diabetes mellitus. Frontiers in Endocrinology 2014; 5: 1-6.

2. Wael Refaie. Assessment of cardiac autonomic neuropathy in long standing type 2 diabetic women. The Egyptian Heart Journal 2014; 66: 63-9.

3. Dimitropoulos G, Tahrani ABD A, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes. World Journal of Diabetes 2014; 5(1):17-39.

4. Pop-Busui R, Herman WH, Feldman EL. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Current Diabetes Reports 2010; 10(4): 276-82.

5. Gandhi RA, Marques JLB, Selvarajah D, Emery CJ, Tesfaye S. Painful diabetic neuropathy is associated with greater autonomic dysfunction than painless diabetic neuropathy. Diabetes Care 2010; 33(7): 1585-90.

6. Hale WE, Stewart RB, Marks RG. Haematological and biochemical laboratory values in an ambulatory elderly population: an analysis of the effects of age, sex and drugs. Age Ageing 1983; 12: 275-84.

7. Mäkimattila S, Schlenzka A, Mäntysaari M, Bergholm R, Summanen P, Saar P, et al. Predictors of abnormal cardiovascular autonomic function measured by frequence domain analysis of heart rate variability and conventional tests in patients with type 1 diabetes. Diabetes Care 2000; 23(11): 1686-93.

8. Gibbons Christopher H, Freeman R. Freeman, treatment induced diabetic neuropathy a reversible painful autonomic neuropathy. Ann Neurol 2010; 67(4): 534-41.

9. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553-79.

10. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, et al. DIAD investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009; 301: 1547-55.

11. Calles-Escand on J, Lovato LC, Simons-Morton DG. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the action to control cardiovascular risk in diabetes (ACCORD) trial. Diab Care 2010; 33(4): 721-7.

12. Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diab Care 2010; 33: 1578-84.

13. Rathmann W, Ziegler D, Jahnke M, Haastert B, Gries FA. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 1993; 10: 820-4.

14. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med 1980; 49: 95-108.

15. Kleiger RE, Miller JP, Bigger JT, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256-62.

16. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91.

17. Kempler P, Tesfaye S, Chaturvedi N, Stevens LK, Webb DJ, Eaton S, Kerényi Zs, et all, and the EURODIAB IDDM Complications Study Group (2002). Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med 2002; 19: 900-9.

18. Ziegler D, Buchholz S, Sohr C, Nourooz-Zadeh J, Roden M. Oxidative stress predicts progression of peripheral and cardiac autonomic nerve dysfunction over 6 years in diabetic patients. Acta Diabetol 2014.

19. Sandireddy R, Yerra VG, Areti A, Komirishetty P, Kumar A. Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on these targets. Int J Endocrinol 2014.

20. Vinik AI. The conductor of the autonomic orchestra. Front Endocrinol 2012; 3: 71.

21. Kuehl M, Stevens MJ. Cardiovascular autonomic neuropathies as complications of diabetes mellitus. Nat Rev Endocrinol 2012; 8: 405-16.

22. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115: 387-97.

23. Low PA, Benrud-Larson LM, Sletten DM, Opfer-Gehrking TL, Weigand SD, O’Brien PC, Suarez GA, et al. Autonomic symptoms and diabetic neuropathy: a population based study. Diab Care 2004; 27: 2942-7

24. Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. Br Med J 1982; 285: 916-8.

25. Corazza I, Barletta G, Guaraldi P, et al. A new integrated instrumental approach to autonomic nervous system assessment. Computer methods and programs in biomedicine 2014; 117: 267-76.

26. Ewing DJ, Campbell IW, Clark BF. Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications. Ann Intern Med 1980; 92: 308-11.

27. Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop- Busui R, Stevens M, et al. On behalf of the Toronto Consensus Panel on Diabetic Neuropathy, Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011; 27: 639-53.

28. Zi-Hui Tang, Fangfang Zeng, Xiaoling Yu. Bayesian estimation of cardiovascular autonomic neuropathy diagnostic test based on short-term heart rate variability without a gold standard. Brit Med J 2014; 4: 1-9.

29. Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) 2004; 107: 539-57.

30. Kadoi Y. Anesthetic considerations in diabetic patients. Part I: preoperative considerations of patients with diabetes mellitus. J Anesth 2010; 24: 739-47.

31. Peter G, Pernille V, Larsen N, Jensen JVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.

32. Maser RE, Lenhard MJ. An overview of the effect of weight loss on cardiovascular autonomic function. Curr Diabetes Rev 2007; 3: 204-11.

33. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Data base Syst Rev 2012.

34. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven P, Zieve FJ. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-39.

35. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 2013; 93: 137-88.

36. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson’s disease. J Neuroinflammation 2008; 5: 19.

37. Manzella D, Barbieri M, Ragno E, Paolisso G. Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. Am J Clin Nutr 2001; 73: 1052-7.